Chardan Capital analyst Matthew Barcus downgrades Oncorus (NASDAQ:ONCR) from Buy to Neutral.
What 5 Analyst Ratings Have To Say About Enanta Pharma
Enanta Pharma (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…